Karyopharm Therapeutics faces default by Sept. 10 on its term loan. CEO Richard Paulson seeks financing as cancer drug Xpovio's future hangs in balance.
A commercial-stage cancer drugmaker with a market cap about one-third the size of its projected 2026 revenues is on the brink of defaulting.
Karyopharm Therapeutics …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
It's crunch time for Karyopharm as company faces potential default next month
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026
Unapproved in US for decades, levosimendan stumbles in phase 3 as Tenax eyes narrow FDA path
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
